"QMC Health is a nanotechnology company founded in 2008 with break-through rapid testing that advances performance through improved nanotech biomarker conjugates. Technology accelerates a wide menu of testing that includes Sepsis, COVID, Long-COVID, UTI, and TBI in qualitative, semi quantitative and quantitative resolutions[/b]"

TBI

Quote:

---

Neurolytixs’ ground-breaking technology is revolutionizing concussion diagnosis. Our proprietary research has identified a number of blood biomarkers that accurately identify brain injury among patients. Developed by Dr. Doug Fraser, a professor, clinician scientist, and Fellow of the Royal College of Physicians and Surgeons of Canada, this technology is the first test of its kind to yield accuracy in concussion diagnosis.

---

Long-COVID

Quote:

---

AUSTIN, TX, Nov. 01, 2022 (GLOBE NEWSWIRE) -- QMC Health Incorporated announced today an agreement with Lawson Health Research Institute for the exclusive rights to novel blood biomarkers that characterize Long COVID disease. The discovery of the biomarkers identified by a research team at Lawson, led by Dr. Douglas Fraser, was recently published in the journal, Molecular Medicine1. QMC Health will use these biomarkers to develop a Long COVID point-of-care rapid test based on its QDX™ HPFIS (High-Performance Fluorescent Immuno-Sensors) for high sensitivity bio-detection and quantification to develop a best-in-class, low-cost rapid diagnostic testing assay platform.

---

I wonder who they are working with for Covid, Sepsis and UTI biomarkers?